Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

AI Conversational Agent to Improve Varenicline Adherence in Women

FY 2024-25

Summary
Tobacco use is the leading preventable cause of death in Canada, contributing to 46,000 deaths annually. Women who smoke face unique biological, social, and cultural barriers, including hormonal fluctuations, faster nicotine metabolism, caregiving responsibilities, stress-induced cravings, and stigma. These factors lead to lower cessation and higher relapse rates in women compared to men. Despite effective pharmacological treatments like varenicline, over 30% of users discontinue it by the second week, greatly reducing quitting success. Addressing gender-specific barriers to adherence is key to improving health outcomes for women and advancing gender equity. In collaboration with CAMH, the University of Toronto, and Memotext, our team developed an AI chatbot to enhance adherence to varenicline. The chatbot provides personalized support with medication reminders, motivational conversations, and answering questions. This study uses a non-randomized, single-arm, mixed-methods design to evaluate the chatbot's feasibility and its impact on smoking cessation in women. Forty participants will be recruited, focusing on analyzing women experiences to identify barriers and outcomes. Measures will include adherence, acceptability, usability, and smoking cessation success, assessed through surveys, interviews, and chatbot analytics over 12 weeks. This research integrates innovative technology with gender-specific strategies to address women unique needs in smoking cessation. It aims to generate meaningful findings to inform women-centered, equity-focused care, improving health outcomes and advancing women health research. By bridging the gap between effective treatments and real-world application, this work supports scientific excellence in addressing health disparities.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530182
Name
Anjum Sidra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
AI Conversational Agent to Improve Varenicline Adherence in Women
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Addiction; Ai; Implementation Science; Interventions; Mental Health; Pharmacological; Smoking; Smoking Cessation; Technology; Women'S Health
Abstract
Tobacco use is the leading preventable cause of death in Canada, contributing to 46,000 deaths annually. Women who smoke face unique biological, social, and cultural barriers, including hormonal fluctuations, faster nicotine metabolism, caregiving responsibilities, stress-induced cravings, and stigma. These factors lead to lower cessation and higher relapse rates in women compared to men. Despite effective pharmacological treatments like varenicline, over 30% of users discontinue it by the second week, greatly reducing quitting success. Addressing gender-specific barriers to adherence is key to improving health outcomes for women and advancing gender equity. In collaboration with CAMH, the University of Toronto, and Memotext, our team developed an AI chatbot to enhance adherence to varenicline. The chatbot provides personalized support with medication reminders, motivational conversations, and answering questions. This study uses a non-randomized, single-arm, mixed-methods design to evaluate the chatbot's feasibility and its impact on smoking cessation in women. Forty participants will be recruited, focusing on analyzing women experiences to identify barriers and outcomes. Measures will include adherence, acceptability, usability, and smoking cessation success, assessed through surveys, interviews, and chatbot analytics over 12 weeks. This research integrates innovative technology with gender-specific strategies to address women unique needs in smoking cessation. It aims to generate meaningful findings to inform women-centered, equity-focused care, improving health outcomes and advancing women health research. By bridging the gap between effective treatments and real-world application, this work supports scientific excellence in addressing health disparities.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Anjum, Sidra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~